QCG
IMGN

Quadrant Capital Group’s Immunogen Inc IMGN Stock Holding History

Quadrant Capital Group’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-460
Closed -$8.68K – 2785
2023
Q2 		$8.68K Buy
+460
New +$5.43K ﹤0.01% 2056

Other funds holding IMGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Quadrant Capital Group's IMGN Position: Q3 2023 in Review

Quadrant Capital Group sold out of Immunogen Inc (IMGN) in Q3 2023, closing a stake of 460 shares — an estimated $8.68K sold.

Quadrant Capital Group first reported a position in IMGN in Q2 2023 and held it in 1 quarter. The position peaked at $8.68K in Q2 2023. 275 funds tracked by Wall St. Rank hold IMGN as of Q3 2023.

  • Quadrant Capital Group reported no remaining Immunogen Inc position as of Q3 2023 after selling out during the quarter.
  • Quadrant Capital Group sold 460 Immunogen Inc shares in Q3 2023, an estimated $8.68K.
  • Quadrant Capital Group first reported a position in Immunogen Inc in Q2 2023 and held it in 1 quarter.
  • Quadrant Capital Group's Immunogen Inc position peaked at $8.68K in Q2 2023.
  • 275 funds tracked by Wall St. Rank held Immunogen Inc as of Q3 2023.

Based on Quadrant Capital Group's 13F filing for Q3 2023, filed 14 Nov 2023.